Kymera jumps 30% on strong Phase 1b data for KT-621

Kymera Therapeutics surged over 31% pre-market after reporting positive Phase 1b results for KT-621 in moderate to severe atopic dermatitis. The BroADen trial showed STAT6 degradation of 94% in skin and 98% in blood at 100mg and 200mg doses. Retail sentiment on Stocktwits turned bullish as investors reacted to the strong early efficacy signals.